12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Other News

Sarepta Therapeutics, Tekmira, U.S. Department of Defense infectious, drug delivery news

The DoD will continue funding only Tekmira's Ebola medical countermeasure R&D contract after its and Sarepta's contracts were suspended in August due to government budget constraints. The government selected the TKM-Ebola program from Tekmira, which in 2010 received a contract worth up to $140 million by the DoD's Transformational Medical Technologies (TMT) program to advance an RNAi therapeutic utilizing Tekmira's lipid...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >